We are live on ! Find out more
FC

Finepoint Capital Portfolio holdings

AUM $1.95B
1-Year Est. Return 45.61%
This Fund
S&P 500
This Quarter Est. Return
-27.1%
1 Year Est. Return
+45.61%
3 Year Est. Return
+24.83%
5 Year Est. Return
+26.66%
10 Year Est. Return
–
AUM
$1.38B
AUM Growth
+$1.02B
Cap. Flow
+$1.29B
Cap. Flow %
93.55%
Top 10 Hldgs %
92.32%
Holding
28
New
3
Increased
8
Reduced
–
Closed
2

Top Buys

Rank Stock Value
1
QXO
QXO Inc
QXO
+$751M
2
SWTX
SpringWorks Therapeutics
SWTX
+$467K
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$408K
4
ARGX icon
argenx
ARGX
+$202K
5
RLAY icon
Relay Therapeutics
RLAY
+$155K

Top Sells

Rank Stock Value
1
CVIIW
Churchill Capital Corp VII Warrants
CVIIW
+$192K
2
CNDA.WS
Concord Acquisition Corp II Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50
CNDA.WS
+$44.9K

Sector Composition

Rank Sector Weight
1 Industrials 29.51%
2 Healthcare 19.04%
3 Communication Services 11.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QXO
1
QXO Inc
QXO
$16B
$406M 29.51%
+25,750,781
New +$751M
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$774B
$318M 23.14%
+555,000
New +$307M
IWM icon
3
PUT
iShares Russell 2000 ETF
IWM
$82.2B
$235M 17.1%
+1,065,000
New +$228M
LBRDK icon
4
Liberty Broadband Class C
LBRDK
$4.5B
$154M 11.2%
1,994,510
– –
RVMD icon
5
Revolution Medicines
RVMD
$38.1B
$33.2M 2.41%
731,960
+2,496
+0.3% +$109K
ARGX icon
6
argenx
ARGX
$53.7B
$29.5M 2.14%
54,428
+400
+0.7% +$202K
ASND icon
7
Ascendis Pharma A/S
ASND
$17B
$28.4M 2.06%
190,072
+800
+0.4% +$108K
TVTX icon
8
Travere Therapeutics
TVTX
$5.14B
$24.9M 1.81%
1,782,267
+5,539
+0.3% +$57.7K
SWTX
9
DELISTED
SpringWorks Therapeutics
SWTX
$20.9M 1.52%
650,852
+12,500
+2% +$467K
MLTX icon
10
MoonLake Immunotherapeutics
MLTX
$1.59B
$19.6M 1.42%
388,835
– –
SRPT icon
11
Sarepta Therapeutics
SRPT
$1.82B
$16.7M 1.21%
133,535
+700
+0.5% +$96.8K
LKFT
12
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.94B
$16.1M 1.17%
557,762
+15,000
+3% +$408K
ARVN icon
13
Arvinas
ARVN
$518M
$14.1M 1.03%
574,378
– –
ACAD icon
14
Acadia Pharmaceuticals
ACAD
$4.39B
$13.9M 1.01%
905,384
– –
CYTK icon
15
Cytokinetics
CYTK
$10.9B
$13.5M 0.98%
256,449
– –
RLAY icon
16
Relay Therapeutics
RLAY
$4.22B
$11.5M 0.84%
1,626,146
+20,800
+1% +$155K
PRTA icon
17
Prothena Corp
PRTA
$443M
$7.25M 0.53%
433,471
– –
SLDB icon
18
Solid Biosciences
SLDB
$891M
$6.7M 0.49%
961,251
– –
EYPT icon
19
EyePoint Inc
EYPT
$1.09B
$5.65M 0.41%
707,404
– –
IVCPW
20
DELISTED
Swiftmerge Acquisition Corp. Warrants
IVCPW
$39.2K ﹤0.01%
490,000
– –
CDAQW
21
DELISTED
Compass Digital Acquisition Corp. Warrant
CDAQW
$28.1K ﹤0.01%
459,906
– –
MNYWW
22
MoneyHero Ltd Warrants
MNYWW
$26.9K ﹤0.01%
895,000
– –
GATEW
23
DELISTED
Marblegate Acquisition Corp. Warrant
GATEW
$25.3K ﹤0.01%
735,000
– –
LSBPW
24
DELISTED
LakeShore Biopharma Warrants
LSBPW
$24.2K ﹤0.01%
489,999
– –
CLDI icon
25
Calidi Biotherapeutics
CLDI
$2.23M
$14.2K ﹤0.01%
1,042
– –
1
2

Similar funds

NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return

Finepoint Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Finepoint Capital held 28 positions worth $1.38B, up 291% from $352M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

Finepoint Capital deployed $1.29B of net new capital in Q3 2024, opening 3 new positions and adding to 8 existing holdings. Its largest new stake was QXO Inc: 25,750,781 shares worth $406M.

By sector, the portfolio is most concentrated in Industrials at 30% of assets, followed by Healthcare and Communication Services.

On the sell side, the most notable exit was Churchill Capital Corp VII Warrants, an estimated $192K sold.

  • Finepoint Capital's largest Q3 2024 buy was QXO Inc: 25,750,781 shares worth $406M.
  • Finepoint Capital added most to SpringWorks Therapeutics in Q3 2024, an estimated $467K increase.
  • Finepoint Capital fully exited Churchill Capital Corp VII Warrants in Q3 2024, selling an estimated $192K.
  • Finepoint Capital's ten largest holdings make up 92% of its $1.38B portfolio in Q3 2024.
  • Finepoint Capital opened 3 new positions and closed 2 in Q3 2024.
  • Finepoint Capital's portfolio value rose 291% quarter-over-quarter to $1.38B.

Based on Finepoint Capital's 13F filing for Q3 2024, filed 13 Nov 2024.